ORIC
Oric Pharmaceuticals Inc
NASDAQ: ORIC · HEALTHCARE · BIOTECHNOLOGY
$8.99
-3.33% today
Updated 2026-10-29
Market cap
$963.97M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.32
Dividend yield
—
52W range
$7 – $15
Volume
1.6M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
6.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →266 stocks currently score above 75
Price targets
Analyst target
$21.71
+141.49%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.04 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-31.96M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-89.12M | $-100.70M | $-127.85M | $-129.47M | $-41.49M |
| EPS | — | — | — | — | $-1.32 |
| Free cash flow | $-77.22M | $-86.54M | $-113.85M | $-114.08M | $-31.96M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-20 | PISCITELLI, DOMINIC | M | 14,000 | — |
| 2026-10-20 | PISCITELLI, DOMINIC | M | 14,000 | $4.36 |
| 2026-10-01 | HEYMAN, RICHARD A. | M | 3,500 | — |
Peer comparison
Smart narrative
Oric Pharmaceuticals Inc trades at $8.99. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.04, it sits in the safe zone.
Frequently asked questions
What is Oric Pharmaceuticals Inc's stock price?
Oric Pharmaceuticals Inc (ORIC) trades at $8.99.
Is Oric Pharmaceuticals Inc overvalued?
Oric Pharmaceuticals Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Oric Pharmaceuticals Inc (ORIC)?
The 12-month analyst consensus target is $21.71, about 141.5% above the current $8.99. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Oric Pharmaceuticals Inc's Altman Z-Score is 6.04, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-36.81%
Beta0.98
50D MA$12.67
200D MA$11.16
Shares out0.10B
Float0.09B
Short ratio—
Avg volume1.6M
Performance
1 week-31.77%
1 month-30.44%
3 months-20.10%
YTD+13.69%
1 year-28.07%
3 years—
5 years—